

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



September 9, 2019

**National Stock Exchange of India Ltd,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
**NSE Code – SUNPHARMA**

**BSE Ltd,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**BSE Code– 524715**

**Sub:** Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform you that the wholly owned subsidiary of the Company has increased its shareholding in PJSC Biosintez, Russia, by way of purchase of 8698 shares (2391 ordinary shares and 6307 preferred shares) equivalent to 3.04% of PJSC Biosintez under Mandatory Tender Offer.

Post completion of this purchase of shares, the total holding of wholly owned subsidiary company was increased from 96.96% to 100% in PJSC Biosintez.

The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per 'Annexure A'.

This is for your information and record.

Yours faithfully,  
**For Sun Pharmaceutical Industries Limited,**

**Ashok I Bhuta**  
**Compliance Officer**

Enclosures:

1. Annexure A

## Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



### Annexure A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

a) Name of the target entity, details in brief such as size, turnover etc.;	<b>i) Name of the Target Entity :</b> “PJSC Biosintez.” (“Target Entity”)  <b>ii) Details of the Target Entity:</b> 2019 Sales: RUB 2,272 million.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;	The acquisition of shares would not fall within related party transaction(s), as the shares are being acquired by Sun Pharma (Netherlands) BV from the shareholders of PJSC Biosintez,  The shareholding of Sun Pharma (Netherlands) BV (subsidiary company of Sun Pharmaceutical Industries Ltd) in the Target Entity is 96.96%, prior to this purchase of shares and hence the Target Entity was already a subsidiary of the Company.  The promoter/ promoter group/promoter group companies of Sun Pharmaceutical Industries Limited have no interest in the Target Entity.
c) Industry to which the entity being acquired belongs;	Pharmaceuticals
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Acquisition of further 8698 shares (2391 ordinary shares and 6307 preferred shares) equivalent to 3.04% of PJSC Biosintez under Mandatory Tender Offer by Sun Pharma (Netherlands) B.V. Post the aforesaid purchase, Sun Pharma (Netherlands) BV’s current shareholding in the Target Entity has increased from 96.96% to 100%.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.




**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
 Western Express Highway, Goregaon (E),  
 Mumbai - 400 063, Maharashtra, INDIA.  
 Tel. : (91-22) 4324 4324  
 Fax : (91-22) 4324 4343  
 Website : www.sunpharma.com  
 CIN : L24230GJ1993PLC019050



f) Indicative time period for completion of the acquisition;	Completed.
g) Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration paid to shareholders who tendered their respective shares in the Mandatory Tender Offer.
h) Cost of acquisition or the price at which the shares are acquired;	Rubles 54,194,628.60 equivalent to USD 815,201.99
i) Percentage of shareholding / control acquired and / or number of shares acquired;	3.04 %  The shareholding of Sun Pharma (Netherlands) BV (subsidiary company of Sun Pharmaceutical Industries Ltd) in the Target Entity increased from 96.96% to 100% post this purchase of shares.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<b>Brief background:</b> The Target Entity is mainly engaged in the manufacture and marketing of pharmaceutical products used in hospital segment of the market. The company's products include pharmaceuticals for injections, blood substitutes, blood preservatives, ampoules, tablets, ointment, creams, gels, suppositories, API etc. The Target Entity has presence in Russia and CIS countries. <b>Date of incorporation:</b> 1959 <b>Turnover (sales) of last 3 years:</b> 1. Year Apr 2016-March 2017 – RUB 2,922 million 2. Year Apr 2017-March 2018 – RUB 2,373 million 3. Year Apr 2018-March 2019 – RUB 2,272 million

For Sun Pharmaceutical Industries Limited

  
 (Ashok I Bhuta)  
 Compliance Officer

Date: 9<sup>th</sup> September, 2019.